Demand for RABS system is expected to rise in the next few years driven by features such as provision of aseptic safety in critical zone of an isolator and flexibility for interventions like cleanroom. Moreover, efficiency and less capital investment compared to isolator and cleanroom are expected to propel demand for restricted access barrier system in the near future.
The rules and regulations for manufacturing procedure are getting stringent with demand for aseptic and efficient pharmaceutical and medical products, also with need for safety in research and development and manufacturing from toxic and viral product agents is rising which is expected to drive the business for restricted access barrier systems in near future. However, high cost of installation and components and high cost of maintenance are expected to hamper the growth of the global RABS market. Additionally, limited number of suppliers and requirement of trained operators are expected to restrain the global restricted access barrier system market.
Maintaining aseptic conditions in the pharmaceutical and medical industry is of utmost importance in order to avoid any contamination to product. Cleanrooms provide this feature, but in most of the cases these incur high capital. Restricted barrier access system (RABS), introduced around 1995, is a setup which isolates the operator from the operational area, as humans (operator) are supposed to be the major carriers of contaminating agents.
Since its introduction, RABS systems have found applications in industries such as pharmaceutical, medical, and chemical. RABS setup provides protection by physical barrier and dynamic airflow. RABS have posed as an effective alternatives the conventional isolators in terms of cost and efficiency. According to guidelines set up by the International Society for Pharmaceutical Engineering (ISPE), RABS system should provide an airflow of ISO5, it should provide physical barrier for human interventions in the critical zone, and have automated processes and procedures.